Japanese drugmaker Eisai Co Ltd said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated approval in the United States.
About the Author
Japanese drugmaker Eisai Co Ltd said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer’s drug lecanemab, which was recently granted accelerated approval in the United States.
